ArticlePloS one2026
TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) positivity is associated with a favorable response to immune checkpoint blockade (ICB) in urothelial bladder cancer (BLCA). However, the efficacy of ICB in BLCA exhibits considerable heterogeneity, leading to the need for complementary predictive biomarkers. Recent studies suggest that a high degree of plasma cell infiltration is correlated with improved benefit from ICB, but a specific plasma cell marker in BLCA has not been identified. The aim of this study was to evaluate tumor necrosis factor receptor superfamily member 17 (TNFRSF17) as a plasma cell-specific marker in BLCA and test its utility, combined with PD-L1, for patient stratification receiving ICB therapy.
methodsTranscriptomic and clinical data from publicly available cohorts were analyzed. Plasma cell-associated markers were identified based on expression specificity and correlation analyses. The clinical relevance of TNFRSF17, alone and in combination with CD274, was evaluated by comparisons of survival and the response rate. Associations with immunotherapy-related features were examined using established surrogate measures, including the immunophenoscore. In silico deconvolution analyses were performed to characterize the immunogenic tumor microenvironment by comparing distinct immune infiltration patterns and differential gene expression pathways between the subgroups.
resultsPlasma cell infiltration correlated with favorable survival in BLCA patients. Higher expression of TNFRSF17, a plasma cell-specific marker (R = 0.73 ± 0.15; z score = 1.88 ± 0.41), correlated with increased immunophenoscores, more favorable overall survival outcomes (HR = 0.59) and increased responsiveness to ICB therapy. Tumors with concurrent high TNFRSF17 and CD274 expression exhibited the most favorable survival outcomes (HR = 0.38) and demonstrated an immune-inflamed transcriptional profile, including enrichment of antigen presentation and immune signaling pathways.
conclusionsTNFRSF17 serves as a potential marker to characterize an immune-distinct and prognostically favorable subgroup within CD274High tumors, and to refine stratification for ICB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.